Compare Stocks

→ World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNCE Jounce Therapeutics	$1.88 -2.6%	$1.89	$0.58 ▼ $5.87	$98.94M	0.75	2.46 million shs	11.60 million shs
JSPR Jasper Therapeutics	$21.07 -4.4%	$24.91	$4.00 ▼ $31.01	$317.31M	2.22	118,266 shs	55,703 shs
LIFE aTyr Pharma	$1.60 -0.3%	$1.82	$1.08 ▼ $2.70	$108.36M	1.25	502,055 shs	247,434 shs

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNCE Jounce Therapeutics	0.00%	0.00%	0.00%	0.00%	-2.59%
JSPR Jasper Therapeutics	-0.36%	-7.51%	-20.47%	+95.65%	+82.07%
LIFE aTyr Pharma	-1.23%	+0.63%	-16.67%	+3.23%	-21.95%

World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)

Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.

Click here to find out what to do.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
JNCE Jounce Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	2.7116 of 5 stars	3.5	2.0	0.0	0.0	2.7	3.3	0.6
LIFE aTyr Pharma	2.746 of 5 stars	3.4	5.0	0.0	0.0	3.2	1.7	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JNCE Jounce Therapeutics	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	3.00	Buy	$64.17	204.54% Upside
LIFE aTyr Pharma	2.75	Moderate Buy	$23.67	1,383.80% Upside

Current Analyst Ratings

Latest JSPR, JNCE, and LIFE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/3/2024	JSPR Jasper Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
3/28/2024	JSPR Jasper Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$70.00
3/18/2024	JSPR Jasper Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
3/15/2024	LIFE aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
3/15/2024	LIFE aTyr Pharma	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$19.00 ➝ $16.00
3/7/2024	JSPR Jasper Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$80.00
2/21/2024	LIFE aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JNCE Jounce Therapeutics	$82M	1.21	N/A	N/A	$3.54 per share	0.53
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$7.03 per share	N/A
LIFE aTyr Pharma	$350K	309.61	N/A	N/A	$1.54 per share	1.04

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JNCE Jounce Therapeutics	-$50.92M	-$2.56	N/A	N/A	N/A	N/A	-30.90%	-26.31%	N/A
JSPR Jasper Therapeutics	-$64.46M	-$6.20	N/A	N/A	N/A	N/A	-63.21%	-55.07%	5/10/2024 (Estimated)
LIFE aTyr Pharma	-$50.39M	-$0.96	N/A	N/A	N/A	N/A	-49.84%	-39.12%	5/14/2024 (Estimated)

Latest JSPR, JNCE, and LIFE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/14/2024	Q4 2023	LIFE aTyr Pharma	-$0.23	-$0.25	-$0.02	-$0.25	N/A	N/A
3/4/2024	Q4 2023	JSPR Jasper Therapeutics	-$1.65	-$1.50	+$0.15	-$1.50	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
JNCE Jounce Therapeutics	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
LIFE aTyr Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JNCE Jounce Therapeutics	N/A	8.37	8.37
JSPR Jasper Therapeutics	N/A	7.19	7.19
LIFE aTyr Pharma	0.02	6.27	6.27

Ownership

Institutional Ownership

Company	Institutional Ownership
JNCE Jounce Therapeutics	80.66%
JSPR Jasper Therapeutics	79.85%
LIFE aTyr Pharma	61.72%

Insider Ownership

Company	Insider Ownership
JNCE Jounce Therapeutics	6.92%
JSPR Jasper Therapeutics	3.90%
LIFE aTyr Pharma	3.70%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
JNCE Jounce Therapeutics	137	52.63 million	48.99 million	Optionable
JSPR Jasper Therapeutics	45	15.06 million	14.48 million	Optionable
LIFE aTyr Pharma	56	67.94 million	65.43 million	Optionable

JSPR, JNCE, and LIFE Headlines

Source	Headline
	aTyr Pharma (NASDAQ:LIFE) Stock Passes Above 200-Day Moving Average of $1.54 americanbankingnews.com - April 25 at 3:14 AM
	aTyr Pharma Insiders Placed Bullish Bets Worth US$514.6k finance.yahoo.com - April 21 at 3:56 PM
	Atal Incubation Centre - Centre for Cellular and Molecular Biology signs agreement with Thermo Fisher Scientific to advance innovation in India msn.com - April 17 at 5:09 PM
	aTyr Pharma (NASDAQ:LIFE) Stock Price Crosses Above 200 Day Moving Average of $1.54 americanbankingnews.com - April 17 at 3:00 AM
	aTyr Pharma, Inc. (NASDAQ:LIFE) Shares Sold by Stonepine Capital Management LLC marketbeat.com - April 9 at 9:43 PM
	aTyr Pharma to Participate in April Investor Conferences finance.yahoo.com - April 1 at 8:08 AM
	aTyr Pharma to Participate in April Investor Conferences globenewswire.com - April 1 at 8:00 AM
	Short Interest in aTyr Pharma, Inc. (NASDAQ:LIFE) Rises By 167.4% marketbeat.com - March 28 at 2:55 PM
	3 Penny Stocks That Could Be Multibaggers in the Making: March Edition investorplace.com - March 26 at 2:19 PM
	3 Best Stocks to Buy Now, 3/18/2024, According to Top Analysts msn.com - March 18 at 1:04 PM
	aTyr Pharma, Inc.: aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update finanznachrichten.de - March 17 at 8:32 AM
	Recap: aTyr Pharma Q4 Earnings benzinga.com - March 16 at 10:33 AM
	aTyr Pharma Full Year 2023 Earnings: Revenues Disappoint finance.yahoo.com - March 16 at 10:33 AM
	Buy Rating Affirmed for aTyr Pharma as Lead Candidate efzofitimod Advances in Clinical Trials with Solid Financial Footing markets.businessinsider.com - March 15 at 1:55 PM
	aTyr Pharma Inc (LIFE) Reports Full Year 2023 Financial Results and Corporate Progress finance.yahoo.com - March 15 at 1:55 PM
	Q4 2023 aTyr Pharma Inc Earnings Call finance.yahoo.com - March 15 at 1:55 PM
	aTyr Pharma, Inc. (NASDAQ:LIFE) Q4 2023 Earnings Call Transcript finance.yahoo.com - March 15 at 1:55 PM
	LIFE Stock Earnings: aTyr Pharma Misses EPS for Q4 2023 investorplace.com - March 14 at 10:04 PM
	Atyr Pharma: Q4 Earnings Snapshot washingtonpost.com - March 14 at 6:49 PM
	aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update globenewswire.com - March 14 at 4:00 PM
	Options Volatility and Implied Earnings Moves Today, March 14, 2024 msn.com - March 14 at 1:49 PM
	aTyr Pharma's Earnings Outlook benzinga.com - March 13 at 7:52 PM
	Alnylam embarks on road trip-themed campaign to drive earlier diagnosis of hereditary ATTR amyloidosis fiercepharma.com - March 13 at 1:46 PM
	aTyr Pharma is about to announce earnings — here's what Wall Street expects markets.businessinsider.com - March 13 at 1:46 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Jounce Therapeutics

NASDAQ:JNCE

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Jasper Therapeutics

NASDAQ:JSPR

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.

aTyr Pharma

NASDAQ:LIFE

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial